| Literature DB >> 32846024 |
Yonghee Song1, Youngeun Kim1, Sunhyung Ha1, Samantha Sheller-Miller2, Jaekwang Yoo1, Chulhee Choi1,3, Cheol Hyoung Park1.
Abstract
The extracellular vesicles (EVs) research area has grown rapidly because of their pivotal roles in intercellular communications and maintaining homeostasis of individual organism. As a subtype of EVs, exosomes are made via unique biogenesis pathway and exhibit disparate functional and phenotypic characteristics. Functionally, exosomes transfer biological messages from donor cell to recipient cell, which makes exosomes as a novel therapeutic platform delivering therapeutic materials to the target tissue/cell. Currently, both academia and industry try to develop exosome platform-based therapeutics for disease management, some of which are already in clinical trials. In this review, we will discuss focusing on therapeutic values of exosomes, recent advances in therapeutic exosome platform development, and late development of exosome therapeutics in diverse therapeutic areas. © ILIAS Biologics Inc. American Journal of Reproductive Immunology published by John Wiley & Sons Ltd.Entities:
Keywords: clinical trial; exosomes; inflammatory diseases; therapeutic platform
Year: 2020 PMID： 32846024 DOI： 10.1111/aji.13329
Source DB: PubMed Journal: Am J Reprod Immunol ISSN： 1046-7408 Impact factor: 3.886